Developer docs
API playgroundTry for free, no card

Search company profiles

Pharmaron

Full company profile

uuid0004hdv

Namestring
Pharmaron
Legal namestring
Pharmaron
Websiteurl
pharmaron.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Pharmaron is a China-headquartered, Shenzhen-listed (szse:300759) contract research and manufacturing organization (CRO/CDMO) serving the global life sciences industry. Founded in 2004, the company provides fully integrated R&D and manufacturing services spanning small molecules, biologics, cell and gene therapies, ADCs, and protein degraders across the full drug development lifecycle — from target identification and medicinal chemistry through preclinical safety assessment, clinical bioanalysis (including accelerator mass spectrometry), CMC/API manufacturing, and commercial supply. Its core technology platforms include structural biology, DMPK/ADMET, radiolabeled sciences with AMS, high-content screening and cell painting, AAV gene therapy manufacturing, and Watson-LIMS data management, supported by AAALAC-accredited, GLP-compliant facilities across China, the UK, and the US.

The company operates five principal service lines: Laboratory Services (chemistry, biology, DMPK, safety assessment, bioanalysis), Chemistry Manufacturing & Controls (branded as the Pathfinder end-to-end CMC platform), Clinical Development (radiolabeled sciences, early-phase trials, regulatory affairs), Biologics CDMO, and Cell & Gene Therapy CDMO. Specialized platforms include High-Content Screening with cell painting (Operetta, IncuCyte), Integrated Radiolabeled Sciences with LEAMS, Ocular Testing, and Medical Device preclinical services via a 65,000 sq. ft. AAALAC-accredited facility in San Diego. Pharmaron has conducted over 2,000 safety studies and maintains regulatory compliance across FDA, OECD, EMA, NMPA, and MHRA frameworks.

Pharmaron's business model is a hybrid of professional services (CRO) and managed services (CDMO) revenue, with project-specific quote-based pricing across FTE staffing, fee-for-service, milestone-based, and risk-sharing engagement models. Revenue is generated through direct enterprise sales to pharmaceutical, biotechnology, and medical device companies across Asia Pacific, North America, and Europe, leveraging seven global facilities and a 10,000+ employee scientific workforce. Notable customers include Eli Lilly (manufacturing partner for oral GLP-1 orforglipron), and the company pursues scientific thought leadership via active participation in WRIB, SOT, and ELRIG conferences, plus proprietary webinar series and a comprehensive Knowledge Center.

Short descriptiontext

Pharmaron is a China-headquartered, publicly listed CRO/CDMO offering fully integrated drug discovery, preclinical, CMC manufacturing, biologics, and cell and gene therapy services to global pharmaceutical, biotechnology, and medical device companies across seven facilities in China, the UK, and the US.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersBeijing, China
HQ citystring
Beijing
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research services, drug discovery services, CDMO manufacturing services, preclinical safety assessment, biologics and CGT services
Industry6 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
NAICS code5 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Pharmaceutical Contract Research and Manufacturing (CRO/CDMO)
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services (CRO)
TypeProfessional Services
Description

Pharmaron generates revenue through providing integrated drug discovery, preclinical development, and clinical research services on a contract basis. Services include laboratory chemistry, structural biology, in vitro/in vivo biology, DMPK, safety assessment, bioanalysis, and clinical development. Revenue is generated through various commercial models including FTE (full-time equivalent) staffing, fee-for-service, milestone-based payments, and risk-sharing arrangements with pharmaceutical and biotech partners.

pharmaron.com
2Contract Manufacturing Services (CDMO)
TypeManaged Services
Description

Revenue from API manufacturing and drug product manufacturing services spanning from late-stage clinical through commercial supply. Services include process chemistry, API manufacturing, formulation development, drug product manufacturing, and quality assurance. Manufacturing capabilities support global regulatory requirements across multiple geographies.

pharmaron.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1BioInnovate
Description

Formerly CGT Webinar Series - ongoing collection of webinars focused on cell and gene therapy innovation

pharmaron.com
+1 more record
Core offering1 text field

Pharmaron is a contract research organization (CRO) and contract development and manufacturing organization (CDMO) offering fully integrated, end-to-end drug discovery, preclinical, clinical development, and commercial manufacturing services for pharmaceutical, biotechnology, and medical device companies. Core services span laboratory chemistry, biology, DMPK, safety assessment, bioanalysis, small molecule CMC, biologics development, and cell and gene therapy, supported by seven global facilities in China, the UK, and the US.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Over 2,000 safety studies conducted
+1 more record
Product overview1 text field

Pharmaron is a premier life science contract research and manufacturing organization (CRO/CDMO) offering comprehensive, fully integrated R&D and manufacturing service capabilities across the entire drug discovery, preclinical, clinical development, and commercialization process. Its service portfolio is organized around five core offerings: (1) Laboratory Services — covering laboratory chemistry (synthetic, medicinal, computational, DNA-encoded libraries, radiolabelling), structural biology, in vitro and in vivo biology, DMPK/ADMET, safety assessment, bioanalysis, medical device testing, and integrated drug discovery; (2) Chemistry, Manufacturing & Controls (CMC) — spanning small molecule drug substance and drug product development, process chemistry, analytical development, API manufacturing, formulation, and late-stage clinical-to-commercial CDMO manufacturing across China, the UK, and the US, branded as the Pathfinder End-to-End CMC Platform; (3) Clinical Development — including integrated radiolabelled sciences with accelerator mass spectrometry (AMS), early phase clinical research (US and China), regulatory affairs, and clinical trial recruitment; (4) Biologics — combining biologics laboratory services (antibody discovery, protein science, biologics PK) with biologics CDMO capabilities (cell line development, process development, drug substance/product manufacturing); and (5) Cell and Gene Therapy (CGT) — encompassing preclinical studies, CGT bioanalysis, analytical testing, and Gene Therapy CDMO (GMP plasmid DNA, viral vectors). These services support all major therapeutic modalities including small molecules, biologics, cell and gene therapies, ADC and other bioconjugates, and protein degraders. Specialized platforms include High-Content Screening with cell painting, Integrated Radiolabelled Sciences with AMS, and Ocular Testing Services with GLP-compliant toxicology.

Product and service16 records
1Laboratory Services
CategoryDrug Discovery and Preclinical Research
Description

Comprehensive suite of discovery and preclinical R&D capabilities including laboratory chemistry (synthetic chemistry, medicinal chemistry, radiolabelling, computer-aided drug design, DNA-encoded libraries), structural biology, in vitro and in vivo biology, DMPK (ADMET), safety assessment, bioanalysis, and integrated drug discovery for pharmaceutical and biotech clients.

2Chemistry, Manufacturing & Controls (CMC)
CategoryContract Development and Manufacturing (CDMO)
Description

End-to-end small molecule drug substance and drug product development, spanning discovery process chemistry, process chemistry, analytical development, material science, API manufacturing, formulation development, drug product manufacturing, and regulatory filing support, with clinical and commercial-scale manufacturing in China, the UK, and the US.

3Clinical Development
CategoryClinical Research
Description

Integrated clinical development services including radiolabelled sciences (radiolabelling and radiosynthesis, non-clinical and human ADME with radiolabelled compounds, accelerator mass spectrometry), early phase clinical research in the US, clinical development in China, regulatory affairs, and clinical trial recruitment, supporting global regulatory submissions across FDA, EMA, and NMPA standards.

4Biologics Services
CategoryBiologics Development and Manufacturing
Description

End-to-end biologics development including laboratory services (antibody discovery, protein science, biologics PK, safety assessment, large molecule bioanalysis) and biologics CDMO capabilities (IND-enabling services, developability assessment, cell line development, process development, drug substance and drug product manufacturing, analytical services, and quality).

5Cell and Gene Therapy (CGT) Services
CategoryCell and Gene Therapy
Description

Cell and Gene Therapy services including preclinical studies (CGT in vivo pharmacology, safety assessment, ophthalmology), CGT bioanalysis (biodistribution, viral shedding, immunogenicity assays), analytical testing services (cell-based potency assays, GMP analytical platforms), and Gene Therapy CDMO (GMP plasmid DNA manufacturing, viral vector process development, product characterization, GMP gene therapy manufacturing, regulatory dossier authoring).

6Medical Device Testing
CategoryMedical Device Preclinical Testing
Description

GLP-compliant preclinical surgical and interventional research for medical devices across therapeutic indications including cardiovascular, dental, endoscopy, electrophysiology, general surgery, laparoscopy, metabolic, neuromodulation, neurovascular, orthopedic, ocular, peripheral vascular, reconstruction surgery, robotics, and wound care at the San Diego AAALAC-accredited facility.

7Safety Assessment
CategoryPreclinical Safety Assessment
Description

Safety evaluation of new drug candidates across general toxicology, safety pharmacology, genetic toxicology, developmental and reproductive toxicology (DART), immunotoxicity, and specialty areas including ocular, dermal, medical device, and CGT products, with over 2,000 safety studies conducted to support IND and NDA submissions.

8Bioanalysis
CategoryBioanalytical Sciences
Description

GLP and GCP-compliant bioanalytical method development, validation, and sample analysis for small molecules, large molecules, cell and gene therapies, and carbon-14 labeled compounds across discovery through clinical phases, including LC-MS/MS, immunoassay (ELISA, MSD-ECL), flow cytometry, PCR, liquid scintillation counting, and accelerator mass spectrometry.

9Integrated Drug Discovery
CategoryDrug Discovery Programs
Description

End-to-end drug discovery programs from hit identification to preclinical candidate selection, combining target identification and validation, high-content screening, computer-aided drug design, structural biology, in vitro and in vivo biology, DMPK, and bioanalysis, with flexible business models including co-piloting, independent delivery, FTE, risk-sharing, and milestone-based services.

10Ocular Testing Services
CategoryOcular Preclinical Testing
Description

Preclinical ocular drug development including ocular toxicology, ocular efficacy, ocular PK and biodistribution, and ocular device testing, supporting small molecules, biologics, cell therapies (iPSC, RPE), gene therapies (AAV, plasmids), and ocular devices across anterior and posterior segments with OCT, ERG, slit-lamp biomicroscopy, fundus photography, and electroretinography capabilities.

11Pathfinder End-to-End CMC Platform
CategoryCMC Service Platform
Description

Integrated end-to-end CMC platform integrating API process development and manufacturing, material science, drug product development and manufacturing, analytical development and testing, and regulatory support and quality, supporting clinical development and commercial-scale manufacturing across seven global facilities in China, the UK, and the US.

12Integrated Radiolabelled Sciences Platform
CategoryRadiolabelled Sciences
Description

Integrated radiolabelled sciences platform combining radiolabelling and radiosynthesis (Carbon-14 and Tritium), non-clinical ADME with radiolabelled compounds, human AME studies, disposition of radiolabelled biologics, and Accelerator Mass Spectrometry (AMS) capabilities for absolute bioavailability and microdosing studies.

13Accelerator Mass Spectrometry (AMS)
CategorySpecialized Bioanalytical Services
Description

Ultra-sensitive Accelerator Mass Spectrometry platform for radiolabeled absolute bioavailability studies, microdosing, mass balance, and metabolite profiling, with Low Energy AMS (LEAMS) capabilities enabling reduced complexity workflows, carbon-14 microtracers, and integration with LC for LC+LEAMS workflows aligned with ICH M10 bioanalytical guidelines.

14High-Content Screening (HCS)
CategoryIn Vitro Biology and Phenotypic Screening
Description

High-content screening service using automated microscope-based Operetta and IncuCyte systems for hit identification, drug mechanism studies, multiplexed phenotypic readouts, and cell painting applications across 2D, 3D spheroid, and organoid models.

15Cell Painting Assay Service
CategoryPhenotypic Drug Discovery
Description

Cell painting assay using six fluorescent dyes to visualize morphological structures with the Operetta High Content Imaging system, supporting phenotypic profiling, target identification and deconvolution, mechanism of action elucidation, and determination of drug resistance mechanisms.

16Gene Therapy CDMO
CategoryGene Therapy CDMO
Description

Gene Therapy CDMO providing GMP plasmid DNA manufacturing, viral vector process development, product characterization and QC analytics, GMP gene therapy manufacturing, and regulatory dossier authoring and specification justification for gene therapy products.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-11
Description

Eli Lilly is investing $3 billion over ten years in China to expand manufacturing capacity for oral solid drugs, including the GLP-1 pill orforglipron. Pharmaron serves as a local manufacturing partner in China for this initiative, collaborating on production expansion alongside Eli Lilly's Suzhou plant investments.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-10-28
Description

Pharmaron announced acquisition of 82.54% of Biortus Biosciences in China to strengthen structural biology and drug discovery services. The transaction aims to enhance capabilities in protein science, structural analysis, and AI-driven drug design, expanding Pharmaron's global service platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Two-year collaborative project with Pharmaron Biologics and Complement Therapeutics to intensify perfusion processes and standardize/scale AAV manufacturing for systemic diseases. The partnership leverages Pharmaron's expertise in gene therapy development and manufacturing.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint development partnership with CGT Catapult and Pharmaron Biologics focused on AAV manufacturing process intensification for systemic gene therapy diseases. Collaboration aims to standardize perfusion processes and enable scalable, cost-effective production.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Thermo Fisher's PPD clinical research services and broader life science tools portfolio competes with Pharmaron across discovery, clinical, and bioanalytical services. As a much larger incumbent, Thermo Fisher offers wider scope but less integrated CMC/manufacturing relative to Pharmaron's end-to-end model.

TypeDirect peer
Description

Medpace is a mid-sized clinical CRO competing with Pharmaron's clinical development services for biotech and mid-pharma sponsors. While more focused on clinical than discovery/CDMO, Medpace competes in overlapping therapeutic areas and customer segments.

TypeDirect peer
Description

ICON is a major clinical CRO that competes with Pharmaron's clinical development services for Phase I-IV trials, bioanalytical work, and lab services. Both serve global pharma sponsors with full-service clinical offerings.

TypeDirect peer
Description

WuXi AppTec is the closest direct peer to Pharmaron, offering end-to-end CRO and CDMO services across small molecules, biologics, and CGT from a similarly China-rooted platform with global facilities. Both companies compete head-to-head for the same biotech and pharma outsourcing dollars and were named alongside each other as key players in the drug discovery services market.

TypeBroad incumbent
Description

Eurofins operates bioanalytical, CMC, and central laboratory services that overlap with Pharmaron's bioanalysis and drug substance testing capabilities. As a broad life sciences testing incumbent, Eurofins serves many of the same pharma and biotech customers with similar analytical workflows.

TypeDirect peer
Description

IQVIA is a global CRO and clinical development services competitor with overlapping offerings in clinical trial management, bioanalysis, and real-world evidence. Pharmaron's clinical development services and radiolabelled sciences platform directly compete for the same pharmaceutical sponsor contracts.

TypeDirect peer
Description

Labcorp Drug Development / Fortrea competes with Pharmaron across clinical CRO services, central labs, and bioanalytical work. The companies serve the same large pharma sponsors for global clinical development and bioanalytical assay validation.

TypeDirect peer
Description

Charles River is a leading CRO/CDMO with deep overlap with Pharmaron in safety assessment, bioanalysis, DMPK, and biologics manufacturing. Both companies serve large pharma and biotech with preclinical and CMC services and are regularly cited together as top drug discovery service providers.

9Asymchem Laboratories
TypeDirect peer
Description

Asymchem is a China-based CDMO focused on small molecule API and drug product manufacturing that directly competes with Pharmaron's small molecule CMC and API manufacturing services. Both companies serve global pharma with process chemistry and GMP manufacturing.

TypeRegional player
Description

Tigermed is a leading China-based clinical CRO that competes with Pharmaron's clinical development offerings, particularly in China-domestic trials and Asia-Pacific sponsor work. Both companies were founded in China and serve overlapping biotech customers in the region.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles24 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A9 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment4 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharmaron

Pharmaceutical Contract Research and Manufacturing (CRO/CDMO)pharmaron.com

Pharmaron is a China-headquartered, publicly listed CRO/CDMO offering fully integrated drug discovery, preclinical, CMC manufacturing, biologics, and cell and gene therapy services to global pharmaceutical, biotechnology, and medical device companies across seven facilities in China, the UK, and the US.

What Pharmaron does

Pharmaron is a China-headquartered, Shenzhen-listed (szse:300759) contract research and manufacturing organization (CRO/CDMO) serving the global life sciences industry. Founded in 2004, the company provides fully integrated R&D and manufacturing services spanning small molecules, biologics, cell and gene therapies, ADCs, and protein degraders across the full drug development lifecycle — from target identification and medicinal chemistry through preclinical safety assessment, clinical bioanalysis (including accelerator mass spectrometry), CMC/API manufacturing, and commercial supply. Its core technology platforms include structural biology, DMPK/ADMET, radiolabeled sciences with AMS, high-content screening and cell painting, AAV gene therapy manufacturing, and Watson-LIMS data management, supported by AAALAC-accredited, GLP-compliant facilities across China, the UK, and the US.

The company operates five principal service lines: Laboratory Services (chemistry, biology, DMPK, safety assessment, bioanalysis), Chemistry Manufacturing & Controls (branded as the Pathfinder end-to-end CMC platform), Clinical Development (radiolabeled sciences, early-phase trials, regulatory affairs), Biologics CDMO, and Cell & Gene Therapy CDMO. Specialized platforms include High-Content Screening with cell painting (Operetta, IncuCyte), Integrated Radiolabeled Sciences with LEAMS, Ocular Testing, and Medical Device preclinical services via a 65,000 sq. ft. AAALAC-accredited facility in San Diego. Pharmaron has conducted over 2,000 safety studies and maintains regulatory compliance across FDA, OECD, EMA, NMPA, and MHRA frameworks.

Pharmaron's business model is a hybrid of professional services (CRO) and managed services (CDMO) revenue, with project-specific quote-based pricing across FTE staffing, fee-for-service, milestone-based, and risk-sharing engagement models. Revenue is generated through direct enterprise sales to pharmaceutical, biotechnology, and medical device companies across Asia Pacific, North America, and Europe, leveraging seven global facilities and a 10,000+ employee scientific workforce. Notable customers include Eli Lilly (manufacturing partner for oral GLP-1 orforglipron), and the company pursues scientific thought leadership via active participation in WRIB, SOT, and ELRIG conferences, plus proprietary webinar series and a comprehensive Knowledge Center.

Pharmaron firmographics

Firmographics
Name
Pharmaron
Legal name
Pharmaron
Website
https://pharmaron.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Pharmaron is a China-headquartered, publicly listed CRO/CDMO offering fully integrated drug discovery, preclinical, CMC manufacturing, biologics, and cell and gene therapy services to global pharmaceutical, biotechnology, and medical device companies across seven facilities in China, the UK, and the US.
Ownership category
akta.pro rank

Pharmaron industry classification

Industry
Product category
Pharmaceutical Contract Research and Manufacturing (CRO/CDMO)
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)

Keywords

  • Contract research services
  • Drug discovery services
  • CDMO manufacturing services
  • Preclinical safety assessment
  • Biologics and CGT services

Where Pharmaron is headquartered

Location

Headquarters

HQ city
Beijing
HQ country
China
HQ region
Asia

Offices6 records

Markets served

Pharmaron business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Contract Research Services (CRO): Pharmaron generates revenue through providing integrated drug discovery, preclinical development, and clinical research services on a contract basis. Services include laboratory chemistry, structural biology, in vitro/in vivo biology, DMPK, safety assessment, bioanalysis, and clinical development. Revenue is generated through various commercial models including FTE (full-time equivalent) staffing, fee-for-service, milestone-based payments, and risk-sharing arrangements with pharmaceutical and biotech partners.
  2. Contract Manufacturing Services (CDMO): Revenue from API manufacturing and drug product manufacturing services spanning from late-stage clinical through commercial supply. Services include process chemistry, API manufacturing, formulation development, drug product manufacturing, and quality assurance. Manufacturing capabilities support global regulatory requirements across multiple geographies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels9 records

Pharmaron product offering

Product offering

Core offering

Pharmaron is a contract research organization (CRO) and contract development and manufacturing organization (CDMO) offering fully integrated, end-to-end drug discovery, preclinical, clinical development, and commercial manufacturing services for pharmaceutical, biotechnology, and medical device companies. Core services span laboratory chemistry, biology, DMPK, safety assessment, bioanalysis, small molecule CMC, biologics development, and cell and gene therapy, supported by seven global facilities in China, the UK, and the US.

Product overview

Pharmaron is a premier life science contract research and manufacturing organization (CRO/CDMO) offering comprehensive, fully integrated R&D and manufacturing service capabilities across the entire drug discovery, preclinical, clinical development, and commercialization process. Its service portfolio is organized around five core offerings: (1) Laboratory Services — covering laboratory chemistry (synthetic, medicinal, computational, DNA-encoded libraries, radiolabelling), structural biology, in vitro and in vivo biology, DMPK/ADMET, safety assessment, bioanalysis, medical device testing, and integrated drug discovery; (2) Chemistry, Manufacturing & Controls (CMC) — spanning small molecule drug substance and drug product development, process chemistry, analytical development, API manufacturing, formulation, and late-stage clinical-to-commercial CDMO manufacturing across China, the UK, and the US, branded as the Pathfinder End-to-End CMC Platform; (3) Clinical Development — including integrated radiolabelled sciences with accelerator mass spectrometry (AMS), early phase clinical research (US and China), regulatory affairs, and clinical trial recruitment; (4) Biologics — combining biologics laboratory services (antibody discovery, protein science, biologics PK) with biologics CDMO capabilities (cell line development, process development, drug substance/product manufacturing); and (5) Cell and Gene Therapy (CGT) — encompassing preclinical studies, CGT bioanalysis, analytical testing, and Gene Therapy CDMO (GMP plasmid DNA, viral vectors). These services support all major therapeutic modalities including small molecules, biologics, cell and gene therapies, ADC and other bioconjugates, and protein degraders. Specialized platforms include High-Content Screening with cell painting, Integrated Radiolabelled Sciences with AMS, and Ocular Testing Services with GLP-compliant toxicology.

Differentiator

Problem solved

Functional benefit

Brands

  • BioInnovate: Formerly CGT Webinar Series - ongoing collection of webinars focused on cell and gene therapy innovation
  • Pharmaron Pathfinder

Products and services

  • Laboratory Services Comprehensive suite of discovery and preclinical R&D capabilities including laboratory chemistry (synthetic chemistry, medicinal chemistry, radiolabelling, computer-aided drug design, DNA-encoded libraries), structural biology, in vitro and in vivo biology, DMPK (ADMET), safety assessment, bioanalysis, and integrated drug discovery for pharmaceutical and biotech clients.
  • Chemistry, Manufacturing & Controls (CMC) End-to-end small molecule drug substance and drug product development, spanning discovery process chemistry, process chemistry, analytical development, material science, API manufacturing, formulation development, drug product manufacturing, and regulatory filing support, with clinical and commercial-scale manufacturing in China, the UK, and the US.
  • Clinical Development Integrated clinical development services including radiolabelled sciences (radiolabelling and radiosynthesis, non-clinical and human ADME with radiolabelled compounds, accelerator mass spectrometry), early phase clinical research in the US, clinical development in China, regulatory affairs, and clinical trial recruitment, supporting global regulatory submissions across FDA, EMA, and NMPA standards.
  • Biologics Services End-to-end biologics development including laboratory services (antibody discovery, protein science, biologics PK, safety assessment, large molecule bioanalysis) and biologics CDMO capabilities (IND-enabling services, developability assessment, cell line development, process development, drug substance and drug product manufacturing, analytical services, and quality).
  • Cell and Gene Therapy (CGT) Services Cell and Gene Therapy services including preclinical studies (CGT in vivo pharmacology, safety assessment, ophthalmology), CGT bioanalysis (biodistribution, viral shedding, immunogenicity assays), analytical testing services (cell-based potency assays, GMP analytical platforms), and Gene Therapy CDMO (GMP plasmid DNA manufacturing, viral vector process development, product characterization, GMP gene therapy manufacturing, regulatory dossier authoring).
  • Medical Device Testing GLP-compliant preclinical surgical and interventional research for medical devices across therapeutic indications including cardiovascular, dental, endoscopy, electrophysiology, general surgery, laparoscopy, metabolic, neuromodulation, neurovascular, orthopedic, ocular, peripheral vascular, reconstruction surgery, robotics, and wound care at the San Diego AAALAC-accredited facility.
  • Safety Assessment Safety evaluation of new drug candidates across general toxicology, safety pharmacology, genetic toxicology, developmental and reproductive toxicology (DART), immunotoxicity, and specialty areas including ocular, dermal, medical device, and CGT products, with over 2,000 safety studies conducted to support IND and NDA submissions.
  • Bioanalysis GLP and GCP-compliant bioanalytical method development, validation, and sample analysis for small molecules, large molecules, cell and gene therapies, and carbon-14 labeled compounds across discovery through clinical phases, including LC-MS/MS, immunoassay (ELISA, MSD-ECL), flow cytometry, PCR, liquid scintillation counting, and accelerator mass spectrometry.
  • Integrated Drug Discovery End-to-end drug discovery programs from hit identification to preclinical candidate selection, combining target identification and validation, high-content screening, computer-aided drug design, structural biology, in vitro and in vivo biology, DMPK, and bioanalysis, with flexible business models including co-piloting, independent delivery, FTE, risk-sharing, and milestone-based services.
  • Ocular Testing Services Preclinical ocular drug development including ocular toxicology, ocular efficacy, ocular PK and biodistribution, and ocular device testing, supporting small molecules, biologics, cell therapies (iPSC, RPE), gene therapies (AAV, plasmids), and ocular devices across anterior and posterior segments with OCT, ERG, slit-lamp biomicroscopy, fundus photography, and electroretinography capabilities.
  • Pathfinder End-to-End CMC Platform Integrated end-to-end CMC platform integrating API process development and manufacturing, material science, drug product development and manufacturing, analytical development and testing, and regulatory support and quality, supporting clinical development and commercial-scale manufacturing across seven global facilities in China, the UK, and the US.
  • Integrated Radiolabelled Sciences Platform Integrated radiolabelled sciences platform combining radiolabelling and radiosynthesis (Carbon-14 and Tritium), non-clinical ADME with radiolabelled compounds, human AME studies, disposition of radiolabelled biologics, and Accelerator Mass Spectrometry (AMS) capabilities for absolute bioavailability and microdosing studies.
  • Accelerator Mass Spectrometry (AMS) Ultra-sensitive Accelerator Mass Spectrometry platform for radiolabeled absolute bioavailability studies, microdosing, mass balance, and metabolite profiling, with Low Energy AMS (LEAMS) capabilities enabling reduced complexity workflows, carbon-14 microtracers, and integration with LC for LC+LEAMS workflows aligned with ICH M10 bioanalytical guidelines.
  • High-Content Screening (HCS) High-content screening service using automated microscope-based Operetta and IncuCyte systems for hit identification, drug mechanism studies, multiplexed phenotypic readouts, and cell painting applications across 2D, 3D spheroid, and organoid models.
  • Cell Painting Assay Service Cell painting assay using six fluorescent dyes to visualize morphological structures with the Operetta High Content Imaging system, supporting phenotypic profiling, target identification and deconvolution, mechanism of action elucidation, and determination of drug resistance mechanisms.
  • Gene Therapy CDMO Gene Therapy CDMO providing GMP plasmid DNA manufacturing, viral vector process development, product characterization and QC analytics, GMP gene therapy manufacturing, and regulatory dossier authoring and specification justification for gene therapy products.

Quantifiable outcome

  • Over 2,000 safety studies conducted
  • +1 more outcomes

Companies that use Pharmaron

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Pharmaron technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Pharmaron partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major and core.

  • Eli LillymajorStrategic or Co-development Partner · 11 March 2026Eli Lilly is investing $3 billion over ten years in China to expand manufacturing capacity for oral solid drugs, including the GLP-1 pill orforglipron. Pharmaron serves as a local manufacturing partner in China for this initiative, collaborating on production expansion alongside Eli Lilly's Suzhou plant investments.
  • Biortus BiosciencesmajorStrategic or Co-development Partner · 28 October 2025Pharmaron announced acquisition of 82.54% of Biortus Biosciences in China to strengthen structural biology and drug discovery services. The transaction aims to enhance capabilities in protein science, structural analysis, and AI-driven drug design, expanding Pharmaron's global service platform.
  • CGT CatapultcoreStrategic or Co-development PartnerTwo-year collaborative project with Pharmaron Biologics and Complement Therapeutics to intensify perfusion processes and standardize/scale AAV manufacturing for systemic diseases. The partnership leverages Pharmaron's expertise in gene therapy development and manufacturing.
  • Complement TherapeuticscoreStrategic or Co-development PartnerJoint development partnership with CGT Catapult and Pharmaron Biologics focused on AAV manufacturing process intensification for systemic gene therapy diseases. Collaboration aims to standardize perfusion processes and enable scalable, cost-effective production.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Pharmaron competitors and assessment

Company assessment

Broad incumbents

  • Thermo Fisher Scientific (PPD): Thermo Fisher's PPD clinical research services and broader life science tools portfolio competes with Pharmaron across discovery, clinical, and bioanalytical services. As a much larger incumbent, Thermo Fisher offers wider scope but less integrated CMC/manufacturing relative to Pharmaron's end-to-end model.
  • Eurofins Scientific: Eurofins operates bioanalytical, CMC, and central laboratory services that overlap with Pharmaron's bioanalysis and drug substance testing capabilities. As a broad life sciences testing incumbent, Eurofins serves many of the same pharma and biotech customers with similar analytical workflows.

Direct peers

  • Medpace Holdings: Medpace is a mid-sized clinical CRO competing with Pharmaron's clinical development services for biotech and mid-pharma sponsors. While more focused on clinical than discovery/CDMO, Medpace competes in overlapping therapeutic areas and customer segments.
  • ICON plc: ICON is a major clinical CRO that competes with Pharmaron's clinical development services for Phase I-IV trials, bioanalytical work, and lab services. Both serve global pharma sponsors with full-service clinical offerings.
  • WuXi AppTec: WuXi AppTec is the closest direct peer to Pharmaron, offering end-to-end CRO and CDMO services across small molecules, biologics, and CGT from a similarly China-rooted platform with global facilities. Both companies compete head-to-head for the same biotech and pharma outsourcing dollars and were named alongside each other as key players in the drug discovery services market.
  • IQVIA: IQVIA is a global CRO and clinical development services competitor with overlapping offerings in clinical trial management, bioanalysis, and real-world evidence. Pharmaron's clinical development services and radiolabelled sciences platform directly compete for the same pharmaceutical sponsor contracts.
  • Labcorp Drug Development (Fortrea): Labcorp Drug Development / Fortrea competes with Pharmaron across clinical CRO services, central labs, and bioanalytical work. The companies serve the same large pharma sponsors for global clinical development and bioanalytical assay validation.
  • Charles River Laboratories: Charles River is a leading CRO/CDMO with deep overlap with Pharmaron in safety assessment, bioanalysis, DMPK, and biologics manufacturing. Both companies serve large pharma and biotech with preclinical and CMC services and are regularly cited together as top drug discovery service providers.
  • Asymchem Laboratories: Asymchem is a China-based CDMO focused on small molecule API and drug product manufacturing that directly competes with Pharmaron's small molecule CMC and API manufacturing services. Both companies serve global pharma with process chemistry and GMP manufacturing.

Regional players

  • Hangzhou Tigermed: Tigermed is a leading China-based clinical CRO that competes with Pharmaron's clinical development offerings, particularly in China-domestic trials and Asia-Pacific sponsor work. Both companies were founded in China and serve overlapping biotech customers in the region.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Pharmaron social profiles

Digital presence

Pharmaron compliance and trust

Trust signal

Compliance3 records

Pharmaron financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharmaron leadership team

Management profile

Number of profiles

Profiles24 records

Pharmaron subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Pharmaron funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharmaron M&A and investment

M&A and investment

M&A9 records

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmaron

What does Pharmaron do?

Pharmaron is a contract research organization (CRO) and contract development and manufacturing organization (CDMO) offering fully integrated, end-to-end drug discovery, preclinical, clinical development, and commercial manufacturing services for pharmaceutical, biotechnology, and medical device companies. Core services span laboratory chemistry, biology, DMPK, safety assessment, bioanalysis, small molecule CMC, biologics development, and cell and gene therapy, supported by seven global facilities in China, the UK, and the US.

Is Pharmaron a public or private company?

Pharmaron is a private company. It is classified as public and is currently operating.

When was Pharmaron founded?

Pharmaron was founded in 2004. It employs 1,001 to 5,000 people.

Where is Pharmaron based?

Pharmaron is headquartered in Beijing, China, in the Asia region.

How does Pharmaron make money?

Two revenue lines are on record. Contract Research Services (CRO) is the primary driver. The others are contract Manufacturing Services (CDMO).

Who are Pharmaron's main competitors?

Broad incumbents on record are Thermo Fisher Scientific (PPD) and Eurofins Scientific. Direct peers are Medpace Holdings, ICON plc, WuXi AppTec, IQVIA, Labcorp Drug Development (Fortrea), Charles River Laboratories and Asymchem Laboratories. Hangzhou Tigermed is listed as a regional player.

Does Pharmaron have an API?

No public API is recorded for Pharmaron.

What industry is Pharmaron in?

Pharmaron's product category is Pharmaceutical Contract Research and Manufacturing (CRO/CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAA, Small-Molecule API & Intermediates CDMO. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
36krCXO Leaders Join the AI Poker Table: How Top Executives Are Shaping Enterprise AI StrategiesWuXi AppTec shifted from denying AI drug development to partnering with AI firms like Boltz, which uses its synthesizable chemical assets. Other CXOs like GenScript and Pharmaron are investing in automated wet labs, with AI revenue growing. The industry is moving toward a symbiotic division of labor between AI creativity and CXO physical verification.Seeking AlphaHealthcare ETF: China May Control A Key Bottleneck In AI Drug DiscoveryAI drug discovery is shifting to a physical-capacity bottleneck, with China's biotech services sector holding a large share of that capacity. KURE, a healthcare ETF, holds over 27% of AI drug discovery workflow companies, including WuXi AppTec, WuXi Biologics, and Pharmaron, which together control nearly 19% of the global outsourced medical research market.GasgooAI² Robotics and Pharmaron Form Strategic PartnershipAI² Robotics has signed a strategic partnership with Chinese biopharmaceutical firm Pharmaron, combining its brain-inspired embodied large model technology with life sciences expertise to deploy embodied intelligence in pharmaceutical R&D. The collaboration targets manufacturing, chemical, bioscience, analytical and animal testing labs, with demonstration laboratories planned. Earlier in 2025, AI² Robotics deployed Aibao robots at Bloomage Biotech.The Times of IndiaChina's pharma companies are facing a 'monkey problem' that they say is as tough as 'negotiating for an Nvidia chip'Lab monkey prices in China have doubled over the past year to approximately $26,000 per cynomolgus macaque, driven by surging demand from a drug development sector that now accounts for roughly a third of the global innovative pipeline. The shortage is structural rather than supply-driven, affecting biologics and newer drug formats that require extensive toxicology testing, with industry experts projecting shortfalls of 15,000 to 20,000 animals annually through 2028. Contract research organizations with breeding operations, including WuXi AppTec, Pharmaron, and Joinn Laboratories, are positioned to benefit from the price surge, while Cambodia has restarted monkey imports to partially address the gap.Quantum Computing ReportLogical Qubit Technology Unveils AGate Quantum Cloud Platform and Multi-Year RoadmapLogical Qubit Technology Co., Ltd launched its AGate superconducting quantum computing cloud platform at Quantum Day 2026 on July 9, 2026, providing quantum circuit execution support for its 30-qubit and 100-qubit AGate series chips. The platform offers pulse-level control access for advanced research and has already secured ecosystem partners including Pharmaron for biopharma applications and four software developers (Liangguan Zhiyuan, Quantum Emergence, Tongyuan Liangzhi, and UnitaryForge). The company outlined a roadmap targeting fault-tolerant quantum systems by 2030, with milestones including breaking the fault-tolerance threshold in 2027 and achieving applications surpassing classical capabilities by 2028.YicaiglobalLab Monkey Prices in China Top USD29,480 Amid Boom in New Drug R&D, Source SaysThe price of cynomolgus lab monkeys in China has exceeded CNY200,000 (USD29,480), driven by a surge in new drug development with clinical trials exceeding 5,000 for the first time last year. China faces a shortage of around 10,000 lab monkeys against an annual demand of 30,000, with almost all pharma contract research organizations having fully booked their lab monkey reservation schedules. Major CROs including WuXi AppTec, Joinn Laboratories, and Pharmaron have been acquiring monkey farms and building breeding bases since 2018, with Joinn Labs reporting net profit surging 4.8 times in Q1 this year.PandailyZhipingfang Hits $2.8B Valuation as Brain-Like AI Era Dawns, Greater Bay Area's First Embodied AI UnicornZhipingfang has completed a new funding round of approximately 5 billion yuan (~$700 million), pushing its valuation past 20 billion yuan ($2.8 billion) and becoming the Greater Bay Area's first embodied AI unicorn to cross this threshold. The funding attracted an unprecedented convergence of investors including national-level industrial funds, provincial AI funds, insurance and securities firms, and industrial players such as China Biologic Products, Pharmaron, Moutai Group, and China Merchants Capital. The company's NeuroVLA architecture, described as the world's first brain-like embodied intelligence system inspired by the human nervous system, drove the valuation surge from 10 billion to over 20 billion yuan in just four months, completing 12 funding rounds within a single year.PedailyFirst release | Zhihui Square is valued at 20 billion, the largest embodied unicorn in the Greater Bay Area is born.Zhi Ping Fang, a general-purpose intelligent robot company, completed a new financing round raising nearly 5 billion yuan, valuing it at over 20 billion. The company's NeuroVLA model, released in June, is the world's first open-source brain-like VLA with biological movement capabilities. It plans to start its own production line in September 2025, aiming for hundreds of monthly deliveries by December.